Emet Surgical Demonstrates Foundation for Efficient, Effective Surgeon and Pathologist Communication at USCAP Annual Meeting
DENVER and TEL AVIV – March 25, 2024 – Emet Surgical, developers of innovative tools to improve surgery outcomes, is exhibiting its tumor marking and mapping tools in Booth No. 453 at the 113th USCAP annual meeting in Baltimore March 23-28.
TrueMargin™ is an easy-to-use tumor margin-marking system that requires no new tools and no new training for surgeons and can be simply added to the surgical and pathology workflows. TrueMargin overcomes conventional tumor marking that is often incomplete by providing specific in-vivo and ex-vivo location and orientation details.
TrueGastro is a highly visible method of marking the colon for surveillance and surgery. TrueGastro is intended to replace marking techniques made ineffective with the shift from open to minimally invasive colon cancer surgeries.
Post approval studies now planned will measure the effectiveness in improving specific communication between both the surgical and pathology teams. We believe the studies will prove the products achieve better outcomes and reduce treatment costs.
“Our mission is clear: to develop tools for doctors that improve their ability to treat patients, rewriting the narrative of cancer survival,” said Bob Witkow, founder and CEO of Emet Surgical. “Too often poor tumor margin marking negatively impacts communication between the surgeon and pathologist which can result in high re-operation rates. We look forward to showcasing how TrueMargin may minimize these types of situations from occurring. Our goal is to deliver products that save patients from additional surgeries and help healthcare systems achieve measurable productivity improvements and cost savings to attendees of the USCAP event.”
Emet Surgical has filed multiple patent applications for tools, how they are produced and how they are packaged. The company’s goal is to secure FDA 510(k) clearance as well as other country registrations with volume production and distribution starting 60 days after clearance. TrueMagin is currently limited by Federal (or United States) law to investigational use.[ms1]
USCAP’s annual meeting is the largest gathering of pathologists in the world. Attendees can catch up on groundbreaking research, learn first-hand from pathology legends, network with their peers, see what’s new in the exhibit hall, and delve deep into a specialty or gain a broader knowledge base. Additional information and registration is available at https://2024am.uscap.org/
Those interested in meeting with Emet Surgical at the conference or wanting to know more about the TrueMargin and TrueGastro products can sign up on the company’s website at https://www.emetsurgical.com
About Emet Surgical
Taking its name from the Hebrew word for “truth,” Emet Surgical is enabling true surgeon/pathologist collaboration. Emet Surgical’s TrueMargin™ tumor margin marking tools, now under regulatory review, are intended to provide surgeons and pathologists with specific in-vivo and ex-vivo tumor margin, location, and orientation details. TrueMargin tools for open, minimally invasive, and robotic procedures enable communication and collaboration not seen before. Founded in 2022, the company is headquartered in Denver with significant operations in in Tel Aviv and Haifa, Israel. Additional information is available at www.EmetSurgical.com or by emailing Info@EmetSurgical.com.
# # #
MEDIA CONTACT:
Mark Smith, JPR Communications
818-398-1424